Trial Profile
A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Patients With Chronic Hepatitis B
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2022
Price :
$35
*
At a glance
- Drugs Entecavir (Primary) ; Vebicorvir (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Assembly Biosciences
- 26 Jun 2022 Results presented at The International Liver Congress 2022
- 26 Jun 2022 Results assessing the associations between the reductions in viral parameters with Fibrosis-4 (FIB-4) index, an indicator of liver health, presented at The International Liver Congress 2022.
- 26 Jun 2022 Results assessing clinical evaluation of VBR 's drug-drug interaction (DDI) potential from Phase 1 (Study 103 ) and Phase 2a (NCT03577171, NCT03576066) studies, presented at The International Liver Congress 2022.